Zimbabwe has rejected a substantial American health deal worth $367m (272 million pounds) over five years due to Washington's insistence on confidential information.
This move was revealed after a government memo dated December was leaked, indicating that President Emmerson Mnangagwa believed the arrangement was "lopsided".
An official representative has since explained that the US was seeking genetic material for scientific study and commercial gain but was not willing to share the resulting advantages from any future treatments.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the United States had donated over $1.9bn as health assistance to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for more talks to secure a deal acceptable to all parties so the country's vital HIV treatment initiative can continue.
Wider Background
This development comes after a similar case in Kenya, where a court suspended a similar deal with the US following concerns were raised about the security of Kenyans' health data.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the key foreign aid agency.
The agency had managed aid for the American government, but Trump argued its expenditure was "inefficient" and his government was pursuing direct bilateral agreements to enhance openness and accountability.
As per reports, Sixteen African countries have to date signed similar agreements, representing over $18.3bn in new funding.
Specifics of the Rejected Agreement
This assistance for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this collaboration might have yielded immense advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy via American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the proposed deal was "unequal".
"Zimbabwe was being asked to surrender its genetic material and health information indefinitely, without any equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might be developed from that shared data," he stated.
"Effectively, our country would provide the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our population if a new pandemic arise."
National Interest and Global Health
He also pointed out that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral deals were upending systems already established through the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to deal with potential global health emergencies.
"This system is intended to ensure that when a country provides its samples, the benefits – such as vaccines and treatments – are distributed fairly, not monopolised solely by those with the funds to create them."
Zimbabwe's reservations over the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We welcome continued discussions with our American counterparts on how subsequent co-operation could be structured in a way that honours the independence and dignity of both nations."
Medical Community Response
A leading public health body said it acknowledged the government's concerns, but suggested that talks need to persist since much of the country's Aids initiatives were funded by foreign aid.
"In cases where technical issues exist, including those relating to information security or agreement terms, these can frequently be addressed through detailed discussion and negotiated safeguards," it added.
The halted deal emphasises the ongoing challenges between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly interconnected world.